Literature DB >> 25048217

Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants.

Damien Marsic1, Lakshmanan Govindasamy2, Seth Currlin1, David M Markusic1, Yu-Shan Tseng3, Roland W Herzog1, Mavis Agbandje-McKenna3, Sergei Zolotukhin1.   

Abstract

Methodologies to improve existing adeno-associated virus (AAV) vectors for gene therapy include either rational approaches or directed evolution to derive capsid variants characterized by superior transduction efficiencies in targeted tissues. Here, we integrated both approaches in one unified design strategy of "virtual family shuffling" to derive a combinatorial capsid library whereby only variable regions on the surface of the capsid are modified. Individual sublibraries were first assembled in order to preselect compatible amino acid residues within restricted surface-exposed regions to minimize the generation of dead-end variants. Subsequently, the successful families were interbred to derive a combined library of ~8 × 10(5) complexity. Next-generation sequencing of the packaged viral DNA revealed capsid surface areas susceptible to directed evolution, thus providing guidance for future designs. We demonstrated the utility of the library by deriving an AAV2-based vector characterized by a 20-fold higher transduction efficiency in murine liver, now equivalent to that of AAV8.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25048217      PMCID: PMC4429732          DOI: 10.1038/mt.2014.139

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  42 in total

1.  Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

Authors:  Lakshmanan Govindasamy; Eric Padron; Robert McKenna; Nicholas Muzyczka; Nikola Kaludov; John A Chiorini; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Enzymatic assembly of DNA molecules up to several hundred kilobases.

Authors:  Daniel G Gibson; Lei Young; Ray-Yuan Chuang; J Craig Venter; Clyde A Hutchison; Hamilton O Smith
Journal:  Nat Methods       Date:  2009-04-12       Impact factor: 28.547

3.  A viral assembly factor promotes AAV2 capsid formation in the nucleolus.

Authors:  Florian Sonntag; Kristin Schmidt; Jürgen A Kleinschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy.

Authors:  Gregory D Hurlbut; Robin J Ziegler; Jennifer B Nietupski; Joseph W Foley; Lisa A Woodworth; Elizabeth Meyers; Scott D Bercury; Nilesh N Pande; David W Souza; Mark P Bree; Michael J Lukason; John Marshall; Seng H Cheng; Ronald K Scheule
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

5.  A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection.

Authors:  Lin Yang; Jiangang Jiang; Lauren M Drouin; Mavis Agbandje-McKenna; Chunlian Chen; Chunping Qiao; Dongqiuye Pu; Xiaoyun Hu; Da-Zhi Wang; Juan Li; Xiao Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

6.  Surface loop dynamics in adeno-associated virus capsid assembly.

Authors:  Nina DiPrimio; Aravind Asokan; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

7.  Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.

Authors:  S Yang; C J Cohen; P D Peng; Y Zhao; L Cassard; Z Yu; Z Zheng; S Jones; N P Restifo; S A Rosenberg; R A Morgan
Journal:  Gene Ther       Date:  2008-05-22       Impact factor: 5.250

8.  Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles.

Authors:  Wuping Li; Aravind Asokan; Zhijian Wu; Terry Van Dyke; Nina DiPrimio; Jarrod S Johnson; Lakshmanan Govindaswamy; Mavis Agbandje-McKenna; Stefan Leichtle; D Eugene Redmond; Thomas J McCown; Kimberly B Petermann; Norman E Sharpless; Richard J Samulski
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

9.  Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.

Authors:  Li Zhong; Baozheng Li; Cathryn S Mah; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Mario Cooper; Roland W Herzog; Irene Zolotukhin; Kenneth H Warrington; Kirsten A Weigel-Van Aken; Jacqueline A Hobbs; Sergei Zolotukhin; Nicholas Muzyczka; Arun Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-29       Impact factor: 11.205

10.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

View more
  31 in total

Review 1.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

2.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

3.  High-Throughput Quantification of In Vivo Adeno-Associated Virus Transduction with Barcoded Non-Coding RNAs.

Authors:  Meiyu Xu; Jia Li; Jun Xie; Ran He; Qin Su; Guangping Gao; Phillip W L Tai
Journal:  Hum Gene Ther       Date:  2019-06-17       Impact factor: 5.695

4.  Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.

Authors:  Zheng Chai; Junjiang Sun; Kelly Michelle Rigsbee; Mei Wang; R Jude Samulski; Chengwen Li
Journal:  J Control Release       Date:  2017-08-05       Impact factor: 9.776

Review 5.  Liver induced transgene tolerance with AAV vectors.

Authors:  Geoffrey D Keeler; David M Markusic; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-12-05       Impact factor: 4.868

6.  Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.

Authors:  Koen Vercauteren; Brad E Hoffman; Irene Zolotukhin; Geoffrey D Keeler; Jing W Xiao; Etiena Basner-Tschakarjan; Katherine A High; Hildegund Cj Ertl; Charles M Rice; Arun Srivastava; Ype P de Jong; Roland W Herzog
Journal:  Mol Ther       Date:  2016-03-29       Impact factor: 11.454

7.  Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.

Authors:  Longping Victor Tse; Kelli A Klinc; Victoria J Madigan; Ruth M Castellanos Rivera; Lindsey F Wells; L Patrick Havlik; J Kennon Smith; Mavis Agbandje-McKenna; Aravind Asokan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

8.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

9.  Capsid Proteins Are Necessary for Replication of a Parvovirus.

Authors:  Thomas Labadie; Deborah Garcia; Doriane Mutuel; Mylène Ogliastro; Guillaume Cambray
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

Review 10.  Next Step in Gene Delivery: Modern Approaches and Further Perspectives of AAV Tropism Modification.

Authors:  Maxim A Korneyenkov; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.